Cargando…
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
Anaplastic Lymphoma Kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL), remains one of the most curable cancers in the paediatric setting; multi-agent chemotherapy cures approximately 65–90% of patients. Over the last two decades, major efforts have focused on improving the survival rate by...
Autores principales: | Prokoph, Nina, Larose, Hugo, Lim, Megan S., Burke, G. A. Amos, Turner, Suzanne D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923354/ https://www.ncbi.nlm.nih.gov/pubmed/29601554 http://dx.doi.org/10.3390/cancers10040099 |
Ejemplares similares
-
Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
por: Hare, Lucy, et al.
Publicado: (2021) -
Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research
por: Deva, Anand K., et al.
Publicado: (2020) -
The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
por: Montes-Mojarro, Ivonne A., et al.
Publicado: (2018) -
BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
por: Garland, Gavin D., et al.
Publicado: (2021) -
Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
por: Mussolin, Lara, et al.
Publicado: (2020)